CSIMarket Company Name, Ticker, Industry, else..
 
Lipocine Inc   (NASDAQ: LPCN)
 
Price: $2.4500 $0.03 1.240%
Day's High: $2.4798998832702637 Week Perf: 9.38 %
Day's Low: $ 2.36 30 Day Perf: 15.02 %
Volume (M): 22,720 52 Wk High: $ 12.37
Volume (M$): $ 0 52 Wk Avg: $4.18
Open: $2.42 52 Wk Low: $1.81



 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 8
 Employees 14
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Lipocine Inc is a pharmaceutical company based in the United States that specializes in the development of oral drug delivery systems. The company focuses on creating innovative solutions to improve the absorption and bioavailability of orally administered drugs. Lipocine aims to address unmet medical needs through their proprietary technology platforms, which include methods to enhance solubility, enable controlled release, and improve overall drug performance. They primarily develop therapies in the areas of men's and women's health, with a particular focus on hormone replacement therapy and reducing the risk of cardiovascular disease.


   Company Address: 675 Arapeen Drive Salt Lake City 84108 UT
   Company Phone Number: 994-7383   Stock Exchange / Ticker: NASDAQ LPCN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABEO        1.35% 
AMRN   -2.43%    
BMRN        2.88% 
ISCO   -19.16%    
TAOX   -0.13%    
VRTX        0.82% 
• View Complete Report
   



Stocks on the Move

Lipocines Breakthrough Bioequivalence Study Results Pave the Way for Revolutionary Pharmacological Treatment

Published Mon, Jul 22 2024 3:35 PM UTC

Lipocine Inc., a renowned biopharmaceutical company, has recently announced groundbreaking results from various studies, demonstrating the bioequivalence of its oral drug candidate, LPCN 1154, to the intravenous (IV) form of brexanolone. These results have the potential to revolutionize the treatment approach for postpartum depression (PPD) and other related conditions. In t...
Stocks on the Move

Lipocine Incs Bioequivalence Studies Demonstrate Promise for Oral Treatment Options

Published Fri, Jun 28 2024 5:29 AM UTC

Lipocine Inc s Positive Study Results on BioequivalenceLipocine Inc., a pharmaceutical company, recently announced positive preliminary results from a pivotal pharmacokinetic study demonstrating the bioequivalence of its drug candidate, LPCN 1154. This milestone achievement showcases the potential of LPCN 1154 as an oral treatment option.In a study conducted by Lipocine, LP...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 12.83
Price to Sales (Expected) -
Price to Book 0.92
PEG (TTM) -

Financial Strength Current
Quick Ratio 11.25
Working Capital Ratio 11.48
Leverage Ratio (MRQ) 0.1
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.87 $
Revenues (TTM) 0.19 $
Cash Flow (TTM) -
Cash 2.83 $
Book Value 2.65 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 112,104
Net Income per Employee (TTM) -846,529
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.08

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -1495.14 %
Net Margin (MRQ) -1379.59 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Lipocine Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.